Aigen Investment Management LP Makes New $151,000 Investment in Liquidia Technologies, Inc. $LQDA

Key Points

• Aigen Investment Management LP invested approximately $151,000 in Liquidia Technologies, Inc. by purchasing 10,213 shares during the first quarter.
• Recent analysts have set varying target prices for LQDA, with Jefferies reaffirming a "buy" rating and a target price of $43.00, while Wells Fargo raised its target from $25.00 to $31.00.
• Insider transactions revealed that CEO Roger Jeffs sold 20,252 shares at an average price of $14.28, which decreased his ownership by 1.91%.

Aigen Investment Management LP acquired a new position in shares of Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,213 shares of the company's stock, valued at approximately $151,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Whitefort Capital Management LP boosted its stake in Liquidia Technologies by 16.8% during the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company's stock worth $23,370,000 after buying an additional 285,220 shares during the period. Vestal Point Capital LP boosted its stake in Liquidia Technologies by 17.3% during the fourth quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company's stock worth $20,698,000 after buying an additional 260,000 shares during the period. Geode Capital Management LLC boosted its stake in Liquidia Technologies by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock worth $15,753,000 after buying an additional 101,597 shares during the period. Tang Capital Management LLC boosted its stake in Liquidia Technologies by 37.5% during the fourth quarter. Tang Capital Management LLC now owns 1,100,000 shares of the company's stock worth $12,936,000 after buying an additional 300,000 shares during the period. Finally, Invesco Ltd. boosted its stake in Liquidia Technologies by 2,675.0% during the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after buying an additional 674,940 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Wall Street Zen upgraded Liquidia Technologies from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Scotiabank lifted their target price on Liquidia Technologies from $36.00 to $37.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, May 28th. Needham & Company LLC lifted their target price on Liquidia Technologies from $32.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Raymond James Financial lifted their target price on Liquidia Technologies from $33.00 to $41.00 and gave the stock a "strong-buy" rating in a research report on Wednesday, August 13th. Finally, Oppenheimer set a $13.00 target price on Liquidia Technologies and gave the stock an "underperform" rating in a research report on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $32.11.

Liquidia Technologies Stock Down 0.2%

Shares of LQDA stock traded down $0.05 on Thursday, hitting $27.30. The stock had a trading volume of 1,540,642 shares, compared to its average volume of 3,346,270. The company has a quick ratio of 2.41, a current ratio of 2.49 and a debt-to-equity ratio of 9.84. The business has a 50 day moving average price of $17.26 and a 200 day moving average price of $15.88. The company has a market cap of $2.35 billion, a PE ratio of -16.06 and a beta of 0.14. Liquidia Technologies, Inc. has a one year low of $8.75 and a one year high of $28.00.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.06). The firm had revenue of $8.84 million during the quarter, compared to the consensus estimate of $3.90 million. Liquidia Technologies had a negative net margin of 732.17% and a negative return on equity of 232.96%. The business's quarterly revenue was up 141.5% compared to the same quarter last year. Research analysts anticipate that Liquidia Technologies, Inc. will post -1.51 earnings per share for the current fiscal year.

Insider Transactions at Liquidia Technologies

In related news, insider Sarah Krepp sold 2,673 shares of Liquidia Technologies stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $14.28, for a total value of $38,170.44. Following the completion of the sale, the insider directly owned 142,499 shares in the company, valued at $2,034,885.72. The trade was a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Rajeev Saggar sold 2,526 shares of Liquidia Technologies stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $14.54, for a total value of $36,728.04. Following the completion of the sale, the insider owned 268,887 shares of the company's stock, valued at $3,909,616.98. The trade was a 0.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,277 shares of company stock valued at $1,469,392 over the last three months. 26.50% of the stock is currently owned by corporate insiders.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).